J&J vaccine

Discussion in 'Wall St. News' started by dealmaker, Feb 2, 2021.

  1. dealmaker

    dealmaker

    J&J vaccine

    How much of a difference will Johnson & Johnson's vaccine make? As Kat Eschner explains in this piece for Fortune, it's less effective than Pfizer/BioNTech and Moderna's vaccines, but a lot easier to roll out: "Many public health officials are pinning their hopes on the one-shot vaccine. In today’s press conference, [Anthony] Fauci underlined the importance of achieving high levels of vaccination, even if some of the vaccines are of lower efficacy." Fortune
     
  2. JSOP

    JSOP

    It's the same as the AstraZeneca one, same underlying mechanism and very similar effective rate in the 70's % range. Personally if it's my turn to get vaccinated, I would want to get the Pfizer one, works for all age group, highest effective rate, effective against largest number of variants (UK, South African and Brazillian), fastest effective starting date (within 7 days of the 2nd booster shot vs 14 days of the Moderna one), lower dosage (30 micrograms vs 100 micrograms from Moderna) and for the same severity of side-effects
     
  3. Pekelo

    Pekelo

    "How much of a difference will Johnson & Johnson's vaccine make? "

    A lot. The first shot of Pfizer is similar in efficiency than J&J, and Fauci is pushing the give just one shot of Pfizer approach, that may be better for society overall. If we can get most people with 70% efficiency that is better than just the elderly with 95%.

    The new vaccines all had zero death and freed up hospitalization. We don't know the long term effect, but psychologically people are real stressed, so a fast 65% is better than a slow 95% to get back to normal.

    Not to mention the logistical hurdle of having to freeze something to -70F in hot climates. (or really anywhere)
     
  4. dealmaker

    dealmaker

    J&J approval

    Johnson & Johnson has asked the U.S. Food and Drug Administration to grant emergency authorization to its COVID-19 vaccine, as it said it would after last week's positive trial results. If approved, this would be the third coronavirus vaccine to be rolled out in the U.S., after those from Pfizer/BioNTech and Moderna. Fortune